Serious Fraud Office Investigation
Issued: London UK – LSE announcement
GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK’s Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group’s commercial practices.
GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.
V A Whyte
27 May 2014
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.